NCT02884544View on ClinicalTrials.gov

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 18, 2016

Study Completion Date

December 27, 2016

Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
DRUG

HLD100

Treatment

Trial Locations (1)

89128

Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas

Sponsors
All Listed Sponsors
lead

Ironshore Pharmaceuticals and Development, Inc

OTHER

NCT02884544 - A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD | Biotech Hunter | Biotech Hunter